Saurabh Chhabra

2 months ago | nature.com | Luciano Costa |Binod Dhakal |Bhagirathbhai Dholaria |Saurabh Chhabra

Response and progression criteria are necessary for any malignancy to standardize assessment of efficacy across trials. In multiple myeloma (MM), the International Myeloma Working Group (IMWG) established universally accepted criteria for response and progressive disease (PD) anchored on serum and urine paraprotein as primary biomarkers of disease burden [1]. The therapeutic landscape of newly diagnosed MM (NDMM) evolves rapidly.

Jan 1, 2025 | jitc.bmj.com | Binod Dhakal |Parameswaran Hari |Saurabh Chhabra |Aniko Szabo

Immune cell therapies and immune cell engineering Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.

Jul 22, 2024 | nature.com | Matthew Rees |Radhika Bansal |Sikander Ailawadhi |Ricardo D. Parrondo |Saurabh Chhabra |Angela Dispenzieri | +9 more

AbstractThree classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid clinicians in selecting between BDTs, we reviewed myeloma patients treated at Mayo Clinic with commercial or investigational BDT between 2018-2023.

Apr 21, 2024 | nature.com | Natalie S. Callander |Jonathan Kaufman |Jacob P. Laubach |Timothy Schmidt |Brandi N. Reeves |Binod Dhakal | +8 more

AbstractIn the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present a post hoc analysis of patients with high-risk cytogenetic abnormalities (HRCAs; del[17p], t[4;14], t[14;16], t[14;20], or gain/amp[1q21]).

Mar 17, 2023 | nature.com | Sham Mailankody |Saurabh Chhabra |Surbhi Sidana

Authors and AffiliationsMyeloma Service and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USASham MailankodyDepartment of Medicine, Weill Cornell Medical College, New York, NY, USASham MailankodyColorado Blood Cancer Institute, Denver, CO, USAJeffrey V.